Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the drug discovery support business, the Company expanded new high-value-added services, completed carried-over contracted studies, secured new orders, and reduced costs by streamlining operations. In the investment and consulting business, it focused on passing through higher costs, optimizing inventory management, reducing fixed costs, and improving gross profit margins through price negotiations.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥13,174,425 thousand (YoY +1.3%) |
| Operating profit | ¥137,960 thousand |
| Ordinary income | ¥118,111 thousand |
| Profit attributable to owners of the parent | ¥-77,267 thousand |
| Net income per share | ¥(4.64) |
| Equity ratio | End of the current fiscal period 49.1 / End of previous period 49.7 |
| Total assets | ¥9,735,359 thousand |
| Net assets | ¥4,839,789 thousand |
| Cash flows from operating activities | ¥25,910 thousand |
| Cash flows from investing activities | ¥50,874 thousand |
| Cash flows from financing activities | ¥-518,460 thousand |
| Cash and cash equivalents at end of period | ¥2,100,212 thousand |
| Full-year earnings forecast | Net Sales ¥14,000 million / Operating profit ¥260 million / Ordinary income ¥200 million / Net income ¥150 million |
| Annual Dividend Forecast | Not disclosed → Undecided |
| Segment revenue | Drug Discovery Support Business ¥2,258,963 thousand (YoY +19.1%), Investment and consulting business ¥10,922,164 thousand (YoY -1.7%) |
| Segment profit | Drug Discovery Support Business ¥-164,119 thousand, Investment and consulting business ¥479,525 thousand (YoY +9.3%) |
| Depreciation and amortization | ¥108,475 thousand |
| Impairment loss | ¥47,072 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥137,520 thousand, Compensation received ¥10,596 thousand, Reversal of consumption taxes and other taxes from prior years ¥26,832 thousand / Extraordinary loss Impairment Losses ¥47,072 thousand, Business restructuring loss ¥143,998 thousand, Compensation paid ¥274,915 thousand, Special investigation expenses and related costs ¥34,512 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Material subsequent events | Not applicable. |
| Factors Behind Changes in Business Performance | In the drug discovery support business, the Company expanded new high-value-added services, completed carried-over contracted studies, secured new orders, and reduced costs by streamlining operations. In the investment and consulting business, it focused on passing through higher costs, optimizing inventory management, reducing fixed costs, and improving gross profit margins through price negotiations. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the drug discovery support business, the Company expanded new high-value-added services, completed carried-over contracted studies, secured new orders, and reduced costs by streamlining operations. In the investment and consulting business, it focused on passing through higher costs, optimizing inventory management, reducing fixed costs, and improving gross profit margins through price negotiations.